Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives Consensus Recommendation of “Hold” from Brokerages

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has been assigned an average rating of “Hold” from the five brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $27.40.

A number of analysts recently weighed in on KMTS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. BTIG Research reaffirmed a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. Finally, The Goldman Sachs Group decreased their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th.

Insiders Place Their Bets

In related news, insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $20.96, for a total transaction of $314,400.00. Following the sale, the insider owned 334,786 shares of the company’s stock, valued at approximately $7,017,114.56. This represents a 4.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 45,000 shares of company stock worth $919,050. Corporate insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC purchased a new position in Kestra Medical Technologies in the 4th quarter worth approximately $31,000. Russell Investments Group Ltd. grew its stake in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after buying an additional 474 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Kestra Medical Technologies in the 3rd quarter worth approximately $48,000. Daiwa Securities Group Inc. purchased a new position in Kestra Medical Technologies in the 4th quarter worth approximately $72,000. Finally, BNP Paribas Financial Markets grew its stake in Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after buying an additional 1,638 shares in the last quarter.

Kestra Medical Technologies Stock Performance

NASDAQ KMTS opened at $19.40 on Friday. The company’s 50 day moving average is $20.65 and its 200-day moving average is $23.30. Kestra Medical Technologies has a 12-month low of $13.25 and a 12-month high of $30.00. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.13 billion, a P/E ratio of -4.90 and a beta of 0.83.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01). The business had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The business’s revenue for the quarter was up 62.7% on a year-over-year basis. Sell-side analysts predict that Kestra Medical Technologies will post -2.34 earnings per share for the current year.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.